Therapeutic applications of nuclear medicine are still at their early stage, but have recently attracted a tremendous interest by big pharma players, as demonstrated by recent acquisitions in this sector. Once approved by healthcare authorities, radiotherapy solutions using radio-isotopes with curative intent are likely to be adopted as a first-line treatment and at a much earlier stage for specific cancers, potentially making them a standard approach in the therapeutic arsenal against cancer in the future.
The effectiveness / side-effect ratio of these treatments will contribute to their successful adoption. It is expected that, following the first marketing authorization for therapeutic nuclear medicine on high-incidence cancers (prostate and breast), interest from large multinational companies will rise, leading to stronger investments and M&A activities in this new field. Currently, Betaglue has under development treatments for primary hepatocellular carcinoma (HCC), and has plans also for other diseases, such as lung and pancreatic cancer.
By overcoming the current limitations of conventional radiotherapy treatments, the global addressable market for BetaGlue Technologies could exceed $5 billion.